NASDAQ:IRMD iRadimed (IRMD) Stock Price, News & Analysis $72.46 -0.57 (-0.77%) As of 12:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About iRadimed Stock (NASDAQ:IRMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get iRadimed alerts:Sign Up Key Stats Today's Range$71.50▼$73.4250-Day Range$56.19▼$73.8552-Week Range$44.58▼$74.00Volume5,581 shsAverage Volume44,843 shsMarket Capitalization$921.63 millionP/E Ratio44.83Dividend Yield0.94%Price Target$72.00Consensus RatingBuy Company Overview IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL. Read More iRadimed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreIRMD MarketRank™: iRadimed scored higher than 92% of companies evaluated by MarketBeat, and ranked 104th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingiRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageiRadimed has received no research coverage in the past 90 days.Read more about iRadimed's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth20.48% Earnings GrowthEarnings for iRadimed are expected to grow by 20.48% in the coming year, from $1.66 to $2.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of iRadimed is 44.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.65.Price to Earnings Ratio vs. SectorThe P/E ratio of iRadimed is 44.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.38.Price to Book Value per Share RatioiRadimed has a P/B Ratio of 9.78. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about iRadimed's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.68% of the float of iRadimed has been sold short.Short Interest Ratio / Days to CoveriRadimed has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in iRadimed has recently decreased by 6.65%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldiRadimed has a dividend yield of 0.92%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthiRadimed has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of iRadimed is 41.98%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, iRadimed will have a dividend payout ratio of 34.00% next year. This indicates that iRadimed will be able to sustain or increase its dividend.Read more about iRadimed's dividend. Sustainability and ESG4.4 / 5Environmental Score-0.85 Percentage of Shares Shorted1.68% of the float of iRadimed has been sold short.Short Interest Ratio / Days to CoveriRadimed has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in iRadimed has recently decreased by 6.65%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.34 News SentimentiRadimed has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for iRadimed this week, compared to 3 articles on an average week.MarketBeat Follows1 people have added iRadimed to their MarketBeat watchlist in the last 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $76,148.00 in company stock.Percentage Held by Insiders36.80% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iRadimed's insider trading history. Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iRadimed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRMD Stock News HeadlinesiRadimed Corporation (NASDAQ:IRMD) Director Sells $76,148.20 in StockAugust 7, 2025 | insidertrades.comIRADIMED CORPORATION to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 26 at 4:05 PM | globenewswire.comThis stock could leave NVDA in the dustInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.August 29 at 2:00 AM | InvestorPlace (Ad)IRadimed: Continued Value Unlock With Extensive Reinvestment RunwayAugust 21, 2025 | seekingalpha.comIradimed Corp’s Earnings Call Highlights Record GrowthAugust 15, 2025 | theglobeandmail.comRoth MKM Remains a Buy on Iradimed (IRMD)August 14, 2025 | theglobeandmail.comThree Days Left Until IRADIMED CORPORATION (NASDAQ:IRMD) Trades Ex-DividendAugust 14, 2025 | finance.yahoo.comAre Robust Financials Driving The Recent Rally In IRADIMED CORPORATION's (NASDAQ:IRMD) Stock?August 12, 2025 | finance.yahoo.comSee More Headlines IRMD Stock Analysis - Frequently Asked Questions How have IRMD shares performed this year? iRadimed's stock was trading at $55.00 on January 1st, 2025. Since then, IRMD shares have increased by 31.7% and is now trading at $72.4550. How were iRadimed's earnings last quarter? iRadimed Corporation (NASDAQ:IRMD) released its earnings results on Thursday, February, 13th. The medical equipment provider reported $0.40 earnings per share for the quarter, missing the consensus estimate of $0.45 by $0.05. The medical equipment provider had revenue of $19.39 million for the quarter, compared to the consensus estimate of $19.09 million. iRadimed had a net margin of 26.61% and a trailing twelve-month return on equity of 23.30%. Read the conference call transcript. Who are iRadimed's major shareholders? Top institutional shareholders of iRadimed include Copeland Capital Management LLC (3.60%), Geode Capital Management LLC (2.05%), Ranger Investment Management L.P. (1.69%) and Acadian Asset Management LLC (1.21%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen, Anthony Vuoto and John Glenn. View institutional ownership trends. How do I buy shares of iRadimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iRadimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Alphabet (GOOG). Company Calendar Last Earnings2/13/2025Record date for 8/28 Dividend8/18/2025Ex-Dividend for 8/28 Dividend8/18/2025Dividend Payable8/28/2025Today8/29/2025Next Earnings (Estimated)10/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:IRMD CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees110Year FoundedN/APrice Target and Rating Average Price Target for iRadimed$72.00 High Price Target$72.00 Low Price Target$72.00 Potential Upside/Downside-0.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$1.62 Trailing P/E Ratio44.83 Forward P/E Ratio43.65 P/E GrowthN/ANet Income$19.23 million Net Margins26.61% Pretax Margin33.53% Return on Equity23.30% Return on Assets20.62% Debt Debt-to-Equity RatioN/A Current Ratio8.78 Quick Ratio7.51 Sales & Book Value Annual Sales$73.24 million Price / Sales12.58 Cash Flow$1.55 per share Price / Cash Flow46.67 Book Value$7.41 per share Price / Book9.78Miscellaneous Outstanding Shares12,720,000Free Float8,039,000Market Cap$921.63 million OptionableOptionable Beta0.94 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:IRMD) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRadimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share iRadimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.